Patricia Ann Mosier, SLP-CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 16534 County Road 164, Iola, TX 77861 Phone: 936-697-4506 |
News Archive
The immunosuppressive drug fingolimod (trade name: Gilenya-) is approved for the treatment of highly-active relapsing-remitting multiple sclerosis (RRMS) in adults. In an early benefit assessment pursuant to "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) assessed whether fingolimod offers an added benefit compared with the present standard therapy.
Nearly half a billion people on the planet have diabetes, but most of them aren't getting the kind of care that could make their lives healthier, longer and more productive, according to a new global study of data from people with the condition.
Liver cancer survival rates could be improved if more people with cirrhosis are screened for tumors using inexpensive ultrasound scans and blood tests, according to a review by doctors at UT Southwestern Medical Center.
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that its United Kingdom subsidiary, Alimera Sciences Limited, has entered into a Loan and Security Agreement with Hercules Technology Growth Capital, Inc. for a term loan in the principal amount of up to $35 million.
Bipolar disorder costs twice as much in lost productivity as major depressive disorder, a study funded by the National Institutes of Health's (NIH) National Institute of Mental Health (NIMH) has found. Each U.S. worker with bipolar disorder averaged 65.5 lost workdays in a year, compared to 27.2 for major depression.
› Verified 5 days ago